Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni.

Date publication

avril 2017

Journal

PLoS neglected tropical diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROMIER Christophe

Tous les auteurs :
Anderson L, Gomes MR, daSilva LF, Pereira ADSA, Mourão MM, Romier C, Pierce R, Verjovski-Almeida S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28406899

Résumé

Schistosomiasis is a parasitic disease infecting hundreds of millions of people worldwide. Treatment depends on a single drug, praziquantel, which kills the Schistosoma spp. parasite only at the adult stage. HDAC inhibitors (HDACi) such as Trichostatin A (TSA) induce parasite mortality in vitro (schistosomula and adult worms), however the downstream effects of histone hyperacetylation on the parasite are not known.

Mots clés

Acetylation, Animals, Chromatin, genetics, DNA Replication, Down-Regulation, Female, Genome, Helminth, Histone Deacetylase Inhibitors, pharmacology, Histones, genetics, Humans, Hydroxamic Acids, pharmacology, Indazoles, pharmacology, Male, Molecular Docking Simulation, Promoter Regions, Genetic, Pyridones, pharmacology, Schistosoma mansoni, drug effects, Transcriptome, Up-Regulation

Référence

PLoS Negl Trop Dis. 2017 Apr;11(4):e0005539